| Autor: |
Zhang PP; a Department of Immunity, Medical College , Nantong University , Nantong , P. R. China., Ding DZ; b Department of Orthopaedics , Affiliated Hospital of Nantong University , Nantong , Jiangsu , P. R. China., Shi B; c Department of Oncology , The Second People's Hospital of Nantong , Nantong , P. R. China., Zhang SQ; d Department of Clinical Laboratory , The Second People's Hospital of Nantong , Nantong , P. R. China., Gu LL; d Department of Clinical Laboratory , The Second People's Hospital of Nantong , Nantong , P. R. China., Wang YC; e Department of Pathogenic Biology, Medical College , Nantong University , Nantong , P. R. China., Cheng C; a Department of Immunity, Medical College , Nantong University , Nantong , P. R. China. |
| Abstrakt: |
Tripartite motif containing 28 (TRIM28) as a transcriptional co-repressor has been reported playing a role in regulating DNA damage response (DDR), cell differentiation, immune response, and tumorigenesis. The present study was performed to explore the biological function and clinical significance of TRIM28 in B-cell non-Hodgkin lymphoma (B-NHL). Results of the study displayed that high expression of TRIM28 was positively associated with the poorer survival of B-NHL patients as an independent prognostic factor. In addition, TRIM28 could promote the B-NHL cells proliferation through modulating cell cycle progression. The change of cyclinA, P21, and PCNA expression after TRIM28 expression modified further illustrated the mechanism in which TRIM28 participated in cell proliferation progression. Moreover, inhibition TRIM28 expression in B-NHL cells enhanced the sensibility to Bortezomib by regulating p53-mediated apoptosis pathway. Taken together, the present study showed that TRIM28 functions as a tumor promoter in B-NHL and may be a novel target for drug resistance to Bortezomib. |
